Ritter ’s RP-G28 mitigates lactose intolerance symptoms in Phase IIb/III trial

US-based Ritter Pharmaceuticals has reported positive additional results from a Phase IIb/III trial of its product candidate RP-G28 in patients suffering from lactose intolerance (LI).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news